Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 13;11(12):004885.
doi: 10.12890/2024_004885. eCollection 2024.

Hepatic Sinusoidal Obstruction Syndrome (SOS) Associated with Checkpoint Inhibitor Therapy

Affiliations

Hepatic Sinusoidal Obstruction Syndrome (SOS) Associated with Checkpoint Inhibitor Therapy

Marianna Litterio et al. Eur J Case Rep Intern Med. .

Abstract

Sinusoidal obstruction syndrome (SOS) is a distinctive and potentially fatal form of hepatic injury that mainly occurs after hematopoietic-stem cell transplantation but also due to many other conditions including drug or toxin exposure. Recently, immune checkpoint inhibitors (ICIs) have revolutionised the treatment of many solid organ malignancies. Furthermore, as their use has become more widespread, rare toxicities have emerged. The difficulty lies in diagnosing these unusual toxicities with an incidence of as low as less than 1% hence defined as SOS. The development of the disease can be rapid and unpredictable. The severe forms of SOS may result in multi-organ dysfunction with a high mortality rate (>80%). We present the case of a patient with metastatic lung adenocarcinoma treated with the ICI pembrolizumab who developed SOS with marked portal hypertension as a rare severe, toxic side effect of immunotherapy. This report highlights the importance of considering SOS in patients who develop liver dysfunction and/or portal hypertension during or after immunotherapy for neoplastic disease. Early identification and severity assessment is crucial in facilitating prompt diagnosis and timely treatment, improving the prognosis of our patients.

Learning points: Understand less common side effects of immunotherapy, now used in daily clinical practice.Consider sinusoidal obstruction syndrome (SOS) in patients who develop liver dysfunction and/or portal hypertension during or after immunotherapy for neoplastic disease.Early identification and severity assessment is crucial in facilitating prompt diagnosis and timely treatment, improving the prognosis of patients.

Keywords: SOS; Sinusoidal obstruction syndrome; immune checkpoint inhibitors; pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interests: The Authors declare that there are no competing interests.

Figures

Figure 1
Figure 1
Computed tomography scan (portal phase). Hepatomegaly with a non-homogeneous intrahepatic vascularization and abundant intra-abdominal effusion.
Figure 2
Figure 2
Dilatation and congestion of sinusoids are located in centrilobular zones around the terminal hepatic vein. Endothelial cells of veins and sinusoids are damaged, leading to hematic deposition in the space of Disse and to hepatocyte necrosis around the central veins. A) Haematoxylin and eosin (H&E) stain; B e C) Masson’s trichrome stain; C) Silver stain.

References

    1. Mavrikou I, Chatzidimitriou D, Skoura L, Nikolousis E, Sakellari I, Gavriilaki E. Molecular Advances in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease. Int J Mol Sci. 2023;24:5620. - PMC - PubMed
    1. Corbacioglu S, Jabbour EJ, Mohty M. Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. Biol Blood Marrow Transplant. 2019;25:1271–1280. - PubMed
    1. Javaid A, Bennett C, Rao A, Spain L. Rare Immune-Related Adverse Events (irAEs): Approach to Diagnosis and Management. Pharmaceut Med. 2024;38:25–38. - PMC - PubMed
    1. Sakumura M, Tajiri K, Miwa S, Nagata K, Kawai K, Miyazono T, et al. Hepatic Sinusoidal Obstruction Syndrome Induced by Non-transplant Chemotherapy for Non-Hodgkin Lymphoma. Intern Med. 2017;56:395–400. - PMC - PubMed
    1. Bonifazi F, Barbato F, Ravaioli F, Sessa M, Defrancesco I, Arpinati M, et al. Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol. 2020;11:489. - PMC - PubMed

LinkOut - more resources